<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30041149</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>24</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1872-9614</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>64-65</Volume>                    <PubDate>                        <MedlineDate>2018 Sep - Oct</MedlineDate>                    </PubDate>                </JournalIssue>                <Title>Nuclear medicine and biology</Title>                <ISOAbbreviation>Nucl. Med. Biol.</ISOAbbreviation>            </Journal>            <ArticleTitle>Predicting response to sepantronium bromide (YM155), a survivin suppressant, by PET imaging with [<sup>11</sup>C]YM155.</ArticleTitle>            <Pagination>                <MedlinePgn>41-46</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0969-8051(17)30333-5</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nucmedbio.2018.06.005</ELocationID>            <Abstract>                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Sepantronium bromide (YM155) is a survivin suppressant that induces apoptosis in tumor cells. Although YM155 induces tumor regression in various tumor types in vivo, phase I and II studies demonstrated responding and non-responding patient populations. We investigated <sup>11</sup>C-labeled YM155 ([<sup>11</sup>C]YM155) used as a positron emission tomography (PET) tracer to assess whether tumor uptake of [<sup>11</sup>C]YM155 correlated with its anti-tumor effect, thereby allowing identification of patients who would respond to YM155 treatment.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">(1) Uptake of YM155 was measured in 39 human cancer cell lines in vitro using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). (2) In vivo tumor uptake was assessed in xenografted mice and total body distribution was evaluated in a cynomolgus monkey using [<sup>11</sup>C]YM155 with PET/computed tomography (CT) (mice) and PET (monkey) imaging.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Intracellular uptake of YM155 in human cancer cell lines correlated well with its in vitro efficacy measured by GI<sub>50</sub> (Pearson's r = -0.5709). Similarly, in vivo studies using tumor xenografted mice showed that tumors sensitive to YM155 demonstrated robust uptake of [<sup>11</sup>C]YM155, whereas insensitive tumors demonstrated low uptake. In the monkey, the biodistribution of [<sup>11</sup>C]YM155 indicated low accumulation in lung, breast, head, and neck and was only significant in organs involved with drug clearance: i.e. liver, kidneys, and bladder.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Robust uptake of [<sup>11</sup>C]YM155 by a tumor appears to be a positive predictive marker for a good response to YM155. The findings suggest the potential utility of PET/CT imaging with [<sup>11</sup>C]YM155 for selection of patients whose tumors are likely to respond to YM155.</AbstractText>                <AbstractText Label="ADVANCES IN KNOWLEDGE" NlmCategory="UNASSIGNED">YM155 efficacy correlated closely with its in vitro intracellular uptake and uptake on [<sup>11</sup>C]YM155 PET imaging. [<sup>11</sup>C]YM155 PET may predict tumor sensitivity to YM155.</AbstractText>                <AbstractText Label="IMPLICATIONS FOR PATIENT CARE" NlmCategory="UNASSIGNED">The concept that tumor response can be accurately predicted prior to chemotherapy should be exploited to improve cancer treatment outcomes through judicious patient selection. The small molecule sepantronium bromide (YM155), a survivin suppressant, has been developed for the treatment of several cancers, including non-Hodgkin lymphoma, lung cancer, and breast cancer. The preferentially high in vitro uptake of YM155 by YM155-sensitive cancer cells and the high in vivo uptake of [<sup>11</sup>C]YM155 in YM155-sensitive tumors demonstrated by PET imaging suggest the potential utility of performing [<sup>11</sup>C]YM155 PET to allow the identification of patients with YM155-sensitive tumors.</AbstractText>                <CopyrightInformation>Copyright © 2018. Published by Elsevier Inc.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Mitsuoka</LastName>                    <ForeName>Keisuke</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kita</LastName>                    <ForeName>Aya</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Murakami</LastName>                    <ForeName>Yoshihiro</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shirasuna</LastName>                    <ForeName>Kenna</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Noda</LastName>                    <ForeName>Akihiro</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yamanaka</LastName>                    <ForeName>Kentaro</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kaneko</LastName>                    <ForeName>Naoki</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Miyoshi</LastName>                    <ForeName>Sosuke</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Japan. Electronic address: sousuke.miyoshi@astellas.com.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>06</Month>                <Day>27</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Nucl Med Biol</MedlineTA>            <NlmUniqueID>9304420</NlmUniqueID>            <ISSNLinking>0969-8051</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Apoptosis</Keyword>            <Keyword MajorTopicYN="N">Neoplasms</Keyword>            <Keyword MajorTopicYN="N">Positron emission tomography</Keyword>            <Keyword MajorTopicYN="N">Survivin</Keyword>            <Keyword MajorTopicYN="N">YM155</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>09</Month>                <Day>29</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>06</Month>                <Day>22</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>06</Month>                <Day>22</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>7</Month>                <Day>25</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>7</Month>                <Day>25</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>7</Month>                <Day>25</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30041149</ArticleId>            <ArticleId IdType="pii">S0969-8051(17)30333-5</ArticleId>            <ArticleId IdType="doi">10.1016/j.nucmedbio.2018.06.005</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>